By now everyone knows that the biggest issue in regard to drug use and costs is specialty medicines that are often complex to make biotech drugs and usually require some special attention for administration, either by injection or infusion. They also may often be covered by a medical benefit instead of the drug benefits, adding to the complexity of their management. The EMD Serono Specialty Digest gives one of the best looks at trends in regard to this category of drugs. Over 100 health plans participated in the survey, representing a large percent of overall covered lives. (Specialty Digest) The three major issues highlighted in the report are management, particularly within medical benefit drugs, member cost share and adherence to avoid waste and ensure the outcomes intended from use of these usually expensive pharmaceuticals. Within management, three primary strategies are the site of care, creative provider reimbursement and use of clinical pathways. More than 85% of plans cover self-administered agents under the drug benefit, while infused or injectables that require provider involvement are typically a medical benefit. 51% of commercial plans have unique cost sharing approaches for specialty drugs, but these plans cover only about 32% of the health plan lives; and 55% of plans have a separate cost share for medical benefit drugs. Coinsurance appears to be becoming more popular as the primary cost share approach. Cost sharing for specialty drugs can be quite large and there are regulatory threats to limit this cost sharing, which of course will only drive up premiums for everyone. Plans are also tending to introduce more tiers of cost-sharing for this category of medicines. Many plans do protect the member to some extent with a maximum out-of-pocket amount. Part D Medicare plans have less flexibility under current rules.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
December 2, 2023
Update on One of the Worst Climate Lies
The infamous Mann hockey stick which showed large temperature rises is revealed to be even…
Commentary
November 30, 2023
How Are Family Finances Really Doing?
A detailed look at American family finances suggests that the wealthy are doing great but…
Commentary
November 30, 2023
Is the Economy “Strong”?
While the economy supposedly is cooking along, unsustainable government and consumer spending are the major…